Mimedx (MDXG) Debt Ratio (2011 - 2026)

Mimedx (MDXG) posted Debt Ratio of 0.06 for Q2 2026, up 7.43% sequentially from 0.06 in Q1 2026, and down 3.44% YoY from 0.06 in Q2 2025.

Mimedx (MDXG) Debt Ratio (2011 - 2026) Analysis & Trends

Mimedx has reported Debt Ratio for 12 years, with the latest figure at 0.06 in Q2 2026.

Quarterly Debt Ratio fell 3.44% year-over-year to 0.06 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 0.06 (down 3.44% YoY) and the FY2025 annual result came in at 0.05, down 26.51% from the prior year.
Debt Ratio advanced to 0.06 in Q2 2026 per MDXG's latest filing, from 0.06 in the prior quarter.
Over five years, Debt Ratio peaked at 0.29 in Q1 2023 and troughed at 0.05 in Q4 2025.
A 5-year average of 0.16 and a median of 0.09 in 2024 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2024: Debt Ratio gained 10.69% in 2022, then sank 69.71% in 2024.
Over 5 years, Debt Ratio stood at 0.28 in 2022, then decreased by 27.54% to 0.21 in 2023, then sank by 65.26% to 0.07 in 2024, then decreased by 26.51% to 0.05 in 2025, then increased by 16.78% to 0.06 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.06, 0.06, and 0.05 for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	0.06

Download Data